Trials / Completed
CompletedNCT05244759
Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
A Single Dose Study to Assess the Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 in Healthy Male Subjects After Oral Dosing
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Bellus Health Inc. - a GSK company · Industry
- Sex
- Male
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of \[14C\]-BLU-5937.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-BLU-5937 | Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state. |
Timeline
- Start date
- 2020-08-25
- Primary completion
- 2020-09-23
- Completion
- 2021-03-02
- First posted
- 2022-02-17
- Last updated
- 2022-02-17
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05244759. Inclusion in this directory is not an endorsement.